<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Burosumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Burosumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Burosumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="117667" href="/d/html/117667.html" rel="external">see "Burosumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="117668" href="/d/html/117668.html" rel="external">see "Burosumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51377548"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Crysvita</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53040776"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Crysvita</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F51341491"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anti-FGF23 Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Parenteral</span></li></ul></div>
<div class="block dop drugH1Div" id="F51392704"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Prior to initiating burosumab, oral phosphates and/or active vitamin D analogs (eg, calcitriol) should be discontinued for at least 1 week. Confirm that baseline fasting serum phosphorus concentration is below the reference range for patient age before initiating burosumab. During burosumab therapy, patients should have 25-hydroxy vitamin D levels monitored; supplement as necessary with cholecalciferol or ergocalciferol to maintain serum 25-hydroxy vitamin D levels in the normal range for age. Dose and interval are age-dependent; use extra precaution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a2d0ce-62ae-4cb6-9568-e0e2d820060d">Hypophosphatemia, X-linked</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypophosphatemia, X-linked (XLH):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months, Children, and Adolescents &lt;18 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight &lt;10 kg: SubQ: 1 mg/<b>kg</b>/dose every <b>2 weeks</b>; calculated dose should be rounded to the nearest 1 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight ≥10 kg: SubQ: 0.8 mg/<b>kg</b>/dose every <b>2 weeks</b>; minimum dose: 10 mg/dose; calculated dose should be rounded to the nearest 10 mg; maximum dose: 90 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: SubQ: 1 mg/<b>kg</b>/dose every <b>4 weeks</b>; calculated dose should be rounded to the nearest 10 mg; maximum dose: 90 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monitoring of therapy:</i> Evaluate fasting serum phosphorus every 4 weeks for first 12 weeks of therapy and as appropriate thereafter (eg, after dosing adjustments). Adjust dose accordingly based on fasting serum phosphorus level; see "Reference Range" for phosphorus age-based normal limits.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosing adjustment based on serum phosphorus:</i></p>
<p style="text-indent:-2em;margin-left:6em;">If <b>low</b> serum phosphorus:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months, Children, and Adolescents &lt;18 years: SubQ:</p>
<p style="text-indent:-2em;margin-left:10em;">Weight &lt;10 kg: If serum phosphorus <b>below</b> the reference range for age, increase dose to 1.5 mg/<b>kg/</b>dose every <b>2 weeks</b>, rounded to the nearest 1 mg. Recheck fasting serum phosphorus 4 weeks after dose adjustment; burosumab should not be adjusted more frequently than every 4 weeks. If needed, dose may be further increased to the maximum dose of 2 mg/<b>kg</b>/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Weight ≥10 kg: If serum phosphorus <b>below</b> the reference range for age, increase dose stepwise based on the following table. Recheck fasting serum phosphorus 4 weeks after dose adjustment; burosumab should not be adjusted more frequently than every 4 weeks. Maximum dose: 2 mg/<b>kg</b>/dose, not to exceed 90 mg/dose.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Weight-Band Dosing for Weight ≥10 kg, Age &lt;18 Years: Fixed Dosing<sup>A</sup> Increases<sup>B </sup>for XLH</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Weight-band (kg)</p></th>
<th align="center">
<p style="text-indent:0em;">Initial dose (mg/dose) every 2 weeks</p></th>
<th align="center">
<p style="text-indent:0em;">1st dose increase to mg/dose every 2 weeks</p></th>
<th align="center">
<p style="text-indent:0em;">2nd dose increase to mg/dose every 2 weeks</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>A </sup>Presented doses already rounded</p>
<p style="text-indent:0em;text-align:left;">
<sup>B</sup> In trials, dose titration for every-2-week dosing was 0.2 mg/kg or 0.3 mg/kg (Carpenter 2018).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;15</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">15</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to &lt;19</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">19 to &lt;32</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">32 to &lt;44</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">60</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">44 to &lt;57</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">60</p></td>
<td align="center">
<p style="text-indent:0em;">80</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">57 to &lt;69</p></td>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">70</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">69 to &lt;81</p></td>
<td align="center">
<p style="text-indent:0em;">60</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">81 to &lt;94</p></td>
<td align="center">
<p style="text-indent:0em;">70</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">94 to &lt;106</p></td>
<td align="center">
<p style="text-indent:0em;">80</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥106</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥18 years: There are no dosage adjustments provided in the manufacturer's labeling for low serum phosphorus.</p>
<p style="text-indent:-2em;margin-left:6em;">If <b>normal</b> serum phosphorus (ie, above the lower limit of reference range for age) and &lt;5 mg/dL: Infants ≥6 months, Children, and Adolescents: Continue current dose; continue to monitor serum phosphorus as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">If <b>high</b> serum phosphorus:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months, Children, and Adolescents &lt;18 years: If serum phosphorus <b>&gt;5 mg/dL</b>: Hold next dose; reassess fasting serum phosphorus in 4 weeks and every 4 weeks thereafter; once serum phosphorus below reference range for age, may reinitiate burosumab at a reduced dose (see the following weight-directed re-initiation recommendations).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Re-initiation dosing: </i>SubQ:</p>
<p style="text-indent:-2em;margin-left:12em;">Patient weight &lt;10 kg: Restart at 0.5 mg/<b>kg</b>/dose every <b>2 weeks</b>; round dose to the nearest 1 mg. Recheck fasting serum phosphorus in 4 weeks and follow dosing adjustment recommendations based on result.</p>
<p style="text-indent:-2em;margin-left:12em;">Patient weight ≥10 kg: See the following table. Recheck fasting serum phosphorus in 4 weeks and follow dosing adjustment recommendations based on result.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Re-Initiation Dosing for Weight ≥10 kg, Age &lt;18 Years: Fixed Dosing for XLH</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Previous dose (mg/dose) every 2 weeks</p></th>
<th align="center">
<p style="text-indent:0em;">Re-initiation dose (mg/dose) every 2 weeks</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">70</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">80</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">90</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥18 years: If serum phosphorus <b>above</b> normal range: Hold next dose; reassess fasting serum phosphorus every 4 weeks; once serum phosphorus falls below the normal range, may reinitiate burosumab at a reduced dose (approximately half the initial starting dose; see the following table [maximum dose: 40 mg/dose]). Recheck fasting serum phosphorus 2 weeks after dose adjustment; based on results, determine if additional dosing adjustment necessary.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Re-Initiation Dosing: Age ≥18 Years for XLH</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Previous dose (mg/dose) every 4 weeks</p></th>
<th align="center">
<p style="text-indent:0em;">Re-initiation dose (mg/dose) every 4 weeks</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">70</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥80</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb71aa17-b365-4c7f-8d9d-36832c9f7323">Osteomalacia, tumor-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomalacia, tumor-induced (TIO):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<i>Initial:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents &lt;18 years: SubQ: 0.4 mg/<b>kg/</b>dose every <b>2 weeks;</b> calculated dose should be rounded to the nearest 10 mg; maximum dose: 180 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: SubQ: 0.5 mg/<b>kg</b>/dose every <b>4 weeks</b>; calculated dose should be rounded to the nearest 10 mg; maximum dose: 180 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monitoring of therapy:</i> During the first 12 weeks of therapy, evaluate fasting serum phosphorus 2 weeks postdose and monthly thereafter or more frequently as appropriate (eg, after dosing adjustments). Adjust dose accordingly based on fasting serum phosphorus level; see "Reference Range" for phosphorus age-based normal limits. Do not adjust more frequently than every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosing adjustment based on serum phosphorus:</i></p>
<p style="text-indent:-2em;margin-left:6em;">If <b>low</b> serum phosphorus:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years and Adolescents &lt;18 years: SubQ: If serum phosphorus <b>below</b> the reference range for age, increase dose stepwise based on the following table. Recheck fasting serum phosphorus 4 weeks after dose adjustment; burosumab should not be adjusted more frequently than every 4 weeks. The following table addresses dose titration only up to 1.5 mg/kg/dose; further increases up to 2 mg/kg/dose may be used; maximum dose: 2 mg/<b>kg</b>/dose, not to exceed 180 mg/dose.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Weight-Band Dosing for Age &lt;18 Years: Fixed Dosing<sup>A</sup> Increases for TIO</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Weight-band (kg)</p></th>
<th align="center">
<p style="text-indent:0em;">Initial dose (mg/dose) every 2 weeks</p></th>
<th align="center">
<p style="text-indent:0em;">1st dose increase to mg/dose every 2 weeks</p></th>
<th align="center">
<p style="text-indent:0em;">2nd dose increase to mg/dose every 2 weeks</p></th>
<th align="center">
<p style="text-indent:0em;">3rd dose increase to mg/dose every 2 weeks</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="5" valign="middle">
<p style="text-indent:0em;">
<sup>A</sup>Table only includes dose titration only up to 1.5 mg/kg/dose; further increases up to 2 mg/kg/dose may be used.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;15</p></td>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">15</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to &lt;19</p></td>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">25</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">19 to &lt;32</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">25</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">32 to &lt;44</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">50</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">44 to &lt;57</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">70</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">57 to &lt;69</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">70</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">69 to &lt;81</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">60</p></td>
<td align="center">
<p style="text-indent:0em;">80</p></td>
<td align="center">
<p style="text-indent:0em;">100</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">81 to &lt;94</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td>
<td align="center">
<p style="text-indent:0em;">70</p></td>
<td align="center">
<p style="text-indent:0em;">100</p></td>
<td align="center">
<p style="text-indent:0em;">120</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">94 to &lt;106</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">80</p></td>
<td align="center">
<p style="text-indent:0em;">110</p></td>
<td align="center">
<p style="text-indent:0em;">140</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥106</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td>
<td align="center">
<p style="text-indent:0em;">130</p></td>
<td align="center">
<p style="text-indent:0em;">160</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥18 years: SubQ: If serum phosphorus <b>below</b> the reference range for age, may increase monthly dose stepwise (see following table) or administer same dose divided every 2 weeks. Burosumab dose should not be adjusted more frequently than every 4 weeks. Maximum dose: 2 mg/<b>kg</b>/dose, not to exceed 180 mg/dose. Recheck fasting serum phosphorus 2 weeks after dose adjustment; burosumab should not be adjusted more frequently than every 4 weeks.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Weight-Based Dosing Increases<sup>A, B </sup>for Age ≥18 years for TIO</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Initial dose</p></th>
<th align="center">
<p style="text-indent:0em;">1st dose increase</p></th>
<th align="center">
<p style="text-indent:0em;">2nd dose increase</p></th>
<th align="center">
<p style="text-indent:0em;">3rd dose increase</p></th>
<th align="center">
<p style="text-indent:0em;">4th dose increase</p></th>
<th align="center">
<p style="text-indent:0em;">5th dose increase</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="6" valign="middle">
<p style="text-indent:0em;">
<sup>A</sup>Round dose to the nearest 10 mg.</p>
<p style="text-indent:0em;">
<sup>B</sup>If the calculated dose is &gt;180 mg every 4 weeks, change to a divided dose administered every 2 weeks. Maximum single dose: 180 mg/dose.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">0.5 mg/kg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg/kg/dose every 4 weeks</p>
<p style="text-indent:0em;">
<b>OR</b></p>
<p style="text-indent:0em;">0.5 mg/kg/dose every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">1.5 mg/kg/dose every 4 weeks</p>
<p style="text-indent:0em;">
<b>OR</b></p>
<p style="text-indent:0em;">0.75 mg/kg/dose every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">2 mg/kg/dose every 4 weeks</p>
<p style="text-indent:0em;">
<b>OR</b></p>
<p style="text-indent:0em;">1 mg/kg every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">1.5 mg/kg/dose every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">2 mg/kg/dose every 2 weeks</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">If <b>normal</b> serum phosphorus:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years and Adolescents: SubQ: If serum phosphorus within reference range for age, continue current dose; continue to monitor serum phosphorus as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">If <b>high</b> serum phosphorus:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥2 years and Adolescents: SubQ: If serum phosphorus above normal reference range for age: hold next dose; reassess fasting serum phosphorus every 4 weeks; once serum phosphorus falls below the reference range for age, may reinitiate burosumab at a reduced dose of approximately half the initial starting dose for age and weight; maximum dose: 180 mg/dose every 2 weeks. Recheck fasting serum phosphorus 4 weeks (if &lt;18 years of age) and 2 weeks (if ≥18 years of age) after dose adjustment; based on results, determine if additional dosing adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose interruption:</i> Children ≥2 years and Adolescents: If underlying tumor is treated (eg, surgical excision or radiation therapy); hold burosumab doses during treatment; after treatment completed, reassess serum phosphorus; if is below the lower limit of normal for age restart burosumab at the original initiation dose for the patient.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51379847"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosing adjustments provided in the manufacturer's labeling (has not been studied); use with caution. Increased serum phosphorus may occur with renal impairment; in addition, burosumab may also cause hyperphosphatemia with risk of nephrocalcinosis; serum phosphorus levels should be monitored very closely.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe renal impairment or end-stage renal disease: Use is contraindicated.</p></div>
<div class="block dohp drugH1Div" id="F51379829"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block doa drugH1Div" id="F51392700"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="117667" href="/d/html/117667.html" rel="external">see "Burosumab: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prior to initiating burosumab, oral phosphate and/or active vitamin D analogs (eg, calcitriol, paricalcitol, doxercalciferol, calcifediol) should be discontinued for at least 1 week; do not administer active vitamin D analogs during burosumab treatment. Confirm baseline fasting serum phosphorus level is below the reference range for patient age before initiating burosumab. Monitor serum 25-hydroxy vitamin D levels; if necessary, supplement with cholecalciferol or ergocalciferol to maintain levels in the normal range for age.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a2d0ce-62ae-4cb6-9568-e0e2d820060d">Hypophosphatemia, X-linked</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Hypophosphatemia, X-linked:</b>
<b>SUBQ:</b> Initial: 1 mg/kg every 4 weeks; calculated dose should be rounded to the nearest 10 mg; maximum dose: 90 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustment based on serum phosphorus: </i>Evaluate fasting serum phosphorus 2 weeks after treatment initiation and continue every 4 weeks for the first 12 weeks of therapy. Adjust dose accordingly based on fasting serum phosphorus level; see Reference Range for phosphorus age-based normal limits. Do not adjust dose more frequently than every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">If <b>low</b> serum phosphorus: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">If <b>normal</b> serum phosphorus: Continue same dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If <b>high</b> serum phosphorus:</p>
<p style="text-indent:-2em;margin-left:8em;">If fasting serum phosphorus <b>above</b> the normal age-based range, withhold next dose and reassess in 4 weeks; once serum phosphorus falls below the age-based normal range, may reinitiate burosumab at approximately one-half the initial starting dose up to a maximum dose of 40 mg every 4 weeks:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Burosumab Reinitiation Dosing</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Previous dose (mg/dose) every 4 weeks</p></th>
<th align="center">
<p style="text-indent:0em;">Reinitiation dose<sup>a</sup> (mg/dose) every 4 weeks</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="2" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Recheck fasting serum phosphorus 2 weeks after dose adjustment; based on results, determine if additional dosing adjustment necessary.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">40</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">70</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥80</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb71aa17-b365-4c7f-8d9d-36832c9f7323">Osteomalacia, tumor-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomalacia, tumor-induced: SUBQ:</b> Initial: 0.5 mg/kg once every 4 weeks; round dose to the nearest 10 mg; maximum dose: 2 mg/kg (not to exceed 180 mg) every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustment based on serum phosphorus: </i>Evaluate fasting serum phosphorus monthly, measured 2 weeks postdose, for the first 3 months of treatment and as clinically necessary thereafter. Adjust dose accordingly based on fasting serum phosphorus level; see "Reference Range" for phosphorus age-based normal limits. Reassess fasting serum phosphorus level 2 weeks after dose adjustment; do not adjust dose more frequently than every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">If serum phosphorus is <b>normal</b>: Continue the same burosumab dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If serum phosphorus is <b>above</b> the normal range: Withhold the next burosumab dose and reassess serum phosphorus in 4 weeks; the serum phosphorus level must be below the reference range to reinitiate burosumab. Reinitiate at approximately one-half of the initial starting dose (up to a maximum of 180 mg every 2 weeks). Reassess serum phosphorus 2 weeks after the dose adjustment. If the level remains below the reference range, the dose can be adjusted upward (see table: "Burosumab Dose Increase Levels for Tumor-Induced Osteomalacia").</p>
<p style="text-indent:-2em;margin-left:6em;">If serum phosphorus is <b>below</b> the normal range: Titrate burosumab dose as follows:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Burosumab Dose Increase Levels For Tumor-Induced Osteomalacia<sup>a,b</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center"></th>
<th align="center">
<p style="text-indent:0em;">Starting dose</p></th>
<th align="center">
<p style="text-indent:0em;">First dose increase<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Second dose increase<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Third dose increase<sup>c</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Fourth dose increase</p></th>
<th align="center">
<p style="text-indent:0em;">Fifth dose increase (maximum dose)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="7" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Round dose to the nearest 10 mg.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>Do not adjust burosumab dose more frequently than every 4 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup>If serum phosphorus is less than the lower limit of the normal range, may consider dividing total dose administered every 4 weeks and administering every 2 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d</sup>If the calculated dose is &gt;180 mg every 4 weeks, change to a divided dose administered every 2 weeks.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">If serum phosphorus is below lower limit of normal 2 weeks postdose adjustment</p></td>
<td align="center">
<p style="text-indent:0em;">0.5 mg/kg every 4 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">Increase to:</p>
<p style="text-indent:0em;">1 mg/kg every 4 weeks</p>
<p style="text-indent:0em;">
<b>Or</b></p>
<p style="text-indent:0em;">0.5 mg/kg every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">Increase to:</p>
<p style="text-indent:0em;">1.5 mg/kg every 4 weeks<sup>d</sup></p>
<p style="text-indent:0em;">
<b>Or</b></p>
<p style="text-indent:0em;">0.75 mg/kg every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">Increase to:</p>
<p style="text-indent:0em;">2 mg/kg every 4 weeks<sup>d</sup></p>
<p style="text-indent:0em;">
<b>Or</b></p>
<p style="text-indent:0em;">1 mg/kg every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">Increase to:</p>
<p style="text-indent:0em;">1.5 mg/kg (not to exceed 180 mg) every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">Increase to:</p>
<p style="text-indent:0em;">2 mg/kg (not to exceed 180 mg) every 2 weeks</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose interruption: </i>Interrupt burosumab therapy if undergoing treatment (eg, surgical excision, radiation therapy) of the underlying tumor; reassess serum phosphorus after underlying tumor treatment is complete. If serum phosphorus remains below the lower limit of normal, reinitiate burosumab at the initiation dose and then adjust as necessary to maintain serum phosphorus within the reference range (see table: "Burosumab Dose Increase Levels for Tumor-Induced Osteomalacia").</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed dose:</i> If a dose is missed, administer as soon as possible. To avoid missed doses, treatments may be administered 3 days on either side of the scheduled treatment date.</p></div>
<div class="block dora drugH1Div" id="F51392746"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F51392747"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F51344067"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema (adults: 11%), skin rash (10% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Vitamin D deficiency (children: 24% to 37%; adults: 7% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (9% to 17%), dental caries (children: 31%), diarrhea (children: 24%), toothache (children: 23%), tooth infection (adults: 13%), vomiting (children: 41% to 48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (14% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Tooth abscess (15% to 34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (children: 52% to 67%; adults: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (10% to 15%), headache (children: 34% to 73%; adults: 11% to 13%), restless leg syndrome (adults: 7% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (adults: 15%), limb pain (children: 38% to 46%), muscle spasm (adults: 7% to 19%), myalgia (children: 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children: 52%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: 44% to 55%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Rash at injection site (children: 10%), urticaria at injection site (children: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperphosphatemia (adults: ≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (children: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (adults: 6% to 22%)</p></div>
<div class="block coi drugH1Div" id="F51341378"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use with oral phosphate and/or active vitamin D analogs (eg, calcitriol, paricalcitol, doxercalciferol, calcifediol); serum phosphorus within or above normal range for age; severe renal impairment or end-stage renal disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to burosumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F51392676"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperphosphatemia: Elevated serum phosphorus may increase the risk of nephrocalcinosis; dose reduction or interruption of therapy may be required. To prevent hyperphosphatemia, interrupt burosumab therapy in patients with tumor-induced osteomalacia receiving treatment for the underlying tumor. Reassess serum phosphorus after underlying tumor-related treatment has been completed; reinitiate and adjust burosumab dose as clinically necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: May cause hypersensitivity reactions (eg, rash, urticaria). Discontinue therapy immediately if serious hypersensitivity reactions occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection site reactions: Local injection site reactions may occur. Most reactions are mild in severity, occur within 1 day of injection, and typically resolve within 1 to 3 days with no treatment. Discontinue use if severe injection site reactions occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Restless leg syndrome: New onset or worsening of existing restless leg syndrome has been reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin D: May decrease serum vitamin D. Monitor serum 25(OH)D levels; supplement with cholecalciferol or ergocalciferol to maintain age-based normal range. Do NOT administer active vitamin D analogs during burosumab treatment.</p></div>
<div class="block foc drugH1Div" id="F51377549"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Crysvita: Burosumab-twza 10 mg/mL (1 mL); Burosumab-twza 20 mg/mL (1 mL); Burosumab-twza 30 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F51377547"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51450727"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Crysvita Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $5,341.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $10,683.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/mL (per mL): $16,025.23</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53040777"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Crysvita: Burosumab-twza 10 mg/mL (1 mL); Burosumab-twza 20 mg/mL (1 mL); Burosumab-twza 30 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614674"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The product is available in multiple concentrations; verify appropriate product selection for dose. Should be administered by a health care provider. Doses may be administered 3 days on either side of a scheduled treatment date to avoid missed dosing. If missed dose falls outside of 3-day window, administer as soon as possible at prescribed dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: SubQ: Administer undiluted SubQ in upper arms, upper thighs, buttocks, or any quadrant of the abdomen; rotate injection sites with each injection. Avoid injection sites where skin is tender, bruised, red, hard, not intact, or areas with moles or scars. The maximum SubQ volume per injection site is 1.5 mL; larger dose volumes need to be split between 2 injection sites. Inspect vial prior to use; do not use if solution is discolored, cloudy, or contains particulate matter.</p></div>
<div class="block adm drugH1Div" id="F51392749"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The product is available in multiple concentrations; verify appropriate product selection for dose. Should be administered by a health care provider.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer SUBQ into the upper thighs, any quadrant of abdomen, buttocks, or upper arms. Contents from 2 vials may be combined; however, the maximum volume per injection site is 1.5 mL. Administer each injection at a different anatomic location than a previous injection. Avoid areas where the skin is tender, bruised, red, hard, or not intact, or where there are scars or moles.</p></div>
<div class="block sts drugH1Div" id="F51392691"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F) in the original carton; do not freeze. Protect from light. Do not shake.</p></div>
<div class="block usep drugH1Div" id="F53571462"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of X-linked hypophosphatemia (XLH) (FDA approved in ages ≥6 months and adults); treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized (FDA approved in ages ≥2 years and adults).</p></div>
<div class="block mst drugH1Div" id="F54500728"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Burosumab may be confused with belimumab, denosumab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F51379754"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F51379751"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: May enhance the adverse/toxic effect of Burosumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May enhance the adverse/toxic effect of Burosumab.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F51392674"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Burosumab is a human IgG monoclonal antibody and may be transferred across the placenta. Maternal serum phosphorus concentrations should be monitored.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to report exposures of burosumab during pregnancy to the manufacturer Adverse Event reporting line (888-756-8657).</p></div>
<div class="block mopp drugH1Div" id="F53571461"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, local injection-site reactions, serum 25-hydroxy vitamin D levels.</p>
<p style="text-indent:-2em;margin-left:2em;">Fasting serum phosphorus levels: Baseline (must be below reference range for therapy initiation); during first 12 weeks of treatment: measure 2 weeks after initial starting dose then every 4 weeks; after first 12 weeks: as clinically appropriate; following dose adjustment: every 4 weeks in age &lt;18 years; every 2 weeks in age ≥18 years (refer to dosing fields for details).</p></div>
<div class="block rerp drugH1Div" id="F53570662"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Reference ranges may vary depending on the laboratory.</p>
<p style="text-indent:-2em;margin-left:2em;">Fasting serum phosphorus: 3.1 to 6.2 mg/dL (SI: 1 to 2 mmol/L) (ASPEN [Corkins 2015]); normal ranges are higher in younger patients. In clinical trials of children 5 to 12 years, a target range of 3.5 to 4.5 mg/dL (SI: 1.1 to 1.5 mmol/L) was used (Carpenter 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Age-directed normal ranges (Kliegman 2020):</p>
<p style="text-indent:-2em;margin-left:6em;">1 to 3 years: 3.8 to 6.5 mg/dL (SI: 1.2 to 2.1 mmol/L).</p>
<p style="text-indent:-2em;margin-left:6em;">4 to 11 years: 3.7 to 5.6 mg/dL (SI: 1.2 to 1.8 mmol/L).</p>
<p style="text-indent:-2em;margin-left:6em;">12 to 15 years: 2.9 to 5.4 mg/dL (SI: 0.9 to 1.7 mmol/L).</p>
<p style="text-indent:-2em;margin-left:6em;">16 to 19 years: 2.7 to 4.7 mg/dL (SI: 0.9 to 1.5 mmol/L).</p></div>
<div class="block pha drugH1Div" id="F51392692"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Burosumab binds to and inhibits the activity of fibroblast growth factor 23, thereby restoring renal phosphate reabsorption and increasing the serum concentration of 1,25 dihydroxy vitamin D.</p></div>
<div class="block phk drugH1Div" id="F51392693"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 8 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Degraded into small peptides and amino acids via catabolic pathways</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~19 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 8 to 11 days</p></div>
<div class="block phksp drugH1Div" id="F51392698"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Body weight: Clearance and volume of distribution of burosumab increases with body weight.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F51377767"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Crysvita</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/burosumab-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29791829">
<a name="29791829"></a>Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-Linked hypophosphatemia. <i>N Engl J Med</i>. 2018;378(21):1987-1998.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/burosumab-pediatric-drug-information/abstract-text/29791829/pubmed" id="29791829" target="_blank">29791829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/burosumab-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. 2nd ed. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crysvita.1">
<a name="Crysvita.1"></a>Crysvita (burosumab-twza) [prescribing information]. Princeton, NJ: Kyowa Kirin Inc; March 2023.</div>
</li>
<li>
<div class="reference">
                  Crysvita (burosumab-twza) [Canadian product monograph]. Bedminster, NJ: Kyowa Kirin Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25919461">
<a name="25919461"></a>Imel EA, Zhang X, Ruppe MD, et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. <i>J Clin Endocrinol Metab</i>. 2015;100(7):2565-2573. doi:10.1210/jc.2015-1551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/burosumab-pediatric-drug-information/abstract-text/25919461/pubmed" id="25919461" target="_blank">25919461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/burosumab-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29679282">
<a name="29679282"></a>Lamb YN. Burosumab: First global approval. <i>Drugs</i>. 2018;78(6):707-714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/burosumab-pediatric-drug-information/abstract-text/29679282/pubmed" id="29679282" target="_blank">29679282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/burosumab-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/burosumab-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 117869 Version 78.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
